Sushma Kumar
Overview
Explore the profile of Sushma Kumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maas B, Strizki J, Miller R, Kumar S, Brown M, Johnson M, et al.
Clin Transl Sci
. 2024 Apr;
17(2):e13732.
PMID: 38593352
Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N-hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC-triphosphate (NHC-TP). NHC-TP...
2.
Orkin C, Molina J, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, et al.
Lancet HIV
. 2023 Dec;
11(2):e75-e85.
PMID: 38141637
Background: In two phase 3 trials for first-line therapy in adults with HIV-1, doravirine showed non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and efavirenz...
3.
Nelson M, Winston A, Hill A, Mngqibisa R, Bassa A, Orkin C, et al.
AIDS
. 2021 Feb;
35(5):759-767.
PMID: 33587439
Objective: Doravirine is an alternative treatment option for individuals who do not tolerate efavirenz. We assessed efficacy, safety, and CNS effects in adults with HIV-1 and CNS complaints who switched...
4.
Orkin C, Squires K, Molina J, Sax P, Sussmann O, Lin G, et al.
Clin Infect Dis
. 2020 Dec;
73(1):33-42.
PMID: 33336698
Background: Doravirine (DOR) is a nonnucleoside reverse-transcriptase inhibitor. In the phase 3 DRIVE-AHEAD trial in treatment-naive adults with human immunodeficiency virus type 1 (HIV-1) infection, DOR demonstrated noninferior efficacy compared...
5.
Martin E, Lai M, Ngo W, Feng M, Graham D, Hazuda D, et al.
J Acquir Immune Defic Syndr
. 2020 Sep;
85(5):635-642.
PMID: 32925358
Background: Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) approved for the treatment of HIV-1 infection in patients with no known DOR resistance-associated mutations. DOR was rationally designed...
6.
Molina J, Squires K, Sax P, Cahn P, Lombaard J, DeJesus E, et al.
Lancet HIV
. 2019 Nov;
7(1):e16-e26.
PMID: 31740348
Background: Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profile, in adults with HIV who were treatment naive...
7.
Wong A, Goldstein D, Mallolas J, DeJesus E, Johnson M, Molina J, et al.
J Acquir Immune Defic Syndr
. 2019 Aug;
82(4):e47-e49.
PMID: 31425317
No abstract available.
8.
Gatell J, Morales-Ramirez J, Hagins D, Thompson M, Arasteh K, Hoffmann C, et al.
Antivir Ther
. 2019 Jul;
24(6):425-435.
PMID: 31355775
Background: The safety and efficacy of doravirine were compared with that of efavirenz as initial treatment of adults living with HIV-1 infection (NCT01632345). Methods: A Phase IIb double-blind trial with...
9.
Orkin C, Molina J, Lombaard J, DeJesus E, Rodgers A, Kumar S, et al.
Clin Infect Dis
. 2019 May;
70(7):1344-1352.
PMID: 31121015
Background: Doravirine (DOR) demonstrated noninferior efficacy to darunavir plus ritonavir (DRV+r) and efavirenz (EFV) in 2 ongoing phase 3 trials: DRIVE-FORWARD (NCT02275780) and DRIVE-AHEAD (NCT02403674). Methods: This prespecified analysis pooled...
10.
Thompson M, Orkin C, Molina J, Sax P, Cahn P, Squires K, et al.
Clin Infect Dis
. 2019 May;
70(7):1336-1343.
PMID: 31121013
Background: A prespecified integrated safety analysis was conducted for 3 doravirine (DOR) double-blind trials (Phase IIb: P007 [NCT01632345]; Phase III: DRIVE-FORWARD [NCT02275780] and DRIVE-AHEAD [NCT02403674]). Methods: DOR (100 mg) arms...